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A Lysosome (Derived from the Greek words Lysis, meaning to “loosen” and 
Soma, “body”) is a structure, covered by a membrane which exists in all animal 
cells except in red blood cell.
This Lysosome is one of the minute bodies seen with the electronic microscope, 
containing various hydrolytic enzymes. Injury to a lysosome is followed by 
release into the cell the enzymes, which can injure the cell. 
The lysosomal storage diseases are a clinically different group of inborn 
errors of metabolism that are classified based upon the biochemical nature of 
incompletely degraded substances which accumulate in different tissue. 
The lysosome maintains an acidified environment, containing catabolic enzymes 
which ease degradation of various byproducts of cellular turnover delivered to 
the lysosome. Phagocytosis and autophagy are other avenue of delivery of these 
substances into the lysosome. 
Absence or deficiency in the hydrolytic activity within the lysosome which 
can be a consequence of mutation within encoding gene is the most common 
cause of the disease. For instance deficient glucocerebrosidase activity in 
Gusher’s disease results in the storage of its substrate, glygosphingolipids, 
glucosylceramide.
There is wide different clinical manifestation of each entity among individually 
affected patients. 
Presentation of disease manifestation may appear at any time from birth till 
adulthood. The variable disease severity between the individual patients seems 
stem from different mutations. The majority of lysosomal storage diseases are 
autosomal recessive disorder.
Heterozygotes or career individuals with a single defective gene often have 
adequate enzyme activity generated by their other alleles.
It is said lysosomal storage disease have a combined prevalence of about 
1/5000-8000 live births and so far 70 of lysosomal storage diseases have been 
described.
As far as treatment is concerned, recombinant human enzymes succeeded 
introduction of enzyme replacement therapy for several disorders, like: 
Gaucher’s, Fabry’s, Pompe’s (Glycogene storage disease II) diseases and 
Haurler-Scheie (MPSI H/S), Hunter’s (MPS II) and Maroteaux-Lamy (MPS 
VI) syndrome. 
Also, enzyme enhancement therapy and gene therapy are considered as other 
ways of lysosoaml storage disease therapies. 
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